← All trials
NCT00244023
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2005
- Primary completion
- Jul 1, 2007
- Completion date
- Jul 1, 2007
- First posted
- —
- Last posted
- —
- Enrollment
- 173
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- SELARL du Dr Jacques BUVATLead sponsor
- Klinikum fur Urologie - Weiden - GermanyOverall official - principal investigator
- Medical University of ViennaOverall official - principal investigator
- University of TampereOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- University of LeedsOverall official - principal investigator
- University of PlymouthOverall official - principal investigator
- University of MalagaOverall official - principal investigator
- CHU Edouard HerriotOverall official - principal investigator
- SELARL du Dr Jacques BUVATStudy chair
- BayerCollaborator
- Free University of AmsterdamOverall official - principal investigator
- Erasmus University RotterdamOverall official - principal investigator
- Vita-Salute University of Milano. ItalyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.